Navigation Links
Vicus Therapeutics' Chief Executive Officer to Participate in BIOTECH 2007 Expert Panels
Date:10/4/2007

MORRISTOWN, N.J., Oct. 4 /PRNewswire/ -- Vicus Therapeutics, LLC, an oncology-focused, clinical-stage, biopharmaceutical company, today announced that John Maki, President and Chief Executive Officer, will participate in two panel discussions titled "Outsourcing: Best Practices and Lessons Learned from an Industry Perspective" and "Exit Strategies: Managing Risk and Reward" at BIOTECH 2007 on Monday, October 8, 2007. The sessions will run from 9:00 a.m. to 10:15 a.m. ET and from 12:30 p.m. to 1:45 p.m. ET, respectively, at the Loews Hotel in Philadelphia, PA.

About BIOTECH 2007

BIOTECH 2007, which is hosted by the BioNJ and Pennsylvania Bio, is designed to enhance the growth and development of the bioscience industry in the New Jersey and Pennsylvania regions. It is an opportunity for entrepreneurs, researchers and executives of emerging and large companies to network and share ideas, strategies and experiences.

About Vicus Therapeutics

Vicus Therapeutics is a privately-held, biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of cancer supportive care indications with an initial focus on cachexia. Vicus' strategy involves combining individual generic drugs that have previously received regulatory approval for other indications and thus have established post-marketing safety records. Vicus leverages its proprietary science to design and patent novel drug combinations that work together to reverse the body's maladaptive responses to cancer and its treatment. Vicus' lead combination product candidate, VT-122, is in Phase 2 clinical trials for the treatment of cancer cachexia in patients with advanced lung cancer. Additionally, Vicus has preclinical-stage combination product candidates being evaluated for the treatment of oral mucositis and cancer fatigue. Vicus' development programs are powered by its network of leading clinical investigators and partners in the US, India and Japan. This international network drives the high quality, rapid and cost effective clinical development of Vicus' product candidates.

For additional information, go to the Company's website:

http://www.vicustherapeutics.com


'/>"/>
SOURCE Vicus Therapeutics, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. State technology chief endorses IT audit recommendations
3. Fusion 2007: CA chief says IT complexity raises risk
4. Web-Based Learning Developed under new Chief Education Officer
5. Chemical-petroleum executive joins Virent Energy board
6. Visions: Matheys says CIO role is good training for executive suite
7. Biotech executive books a career flight thats closer to home
8. CEOs Gone Wild? Risks and rewards in the executive suite
9. Early-stage executives hear from investors
10. Pedlar the latest executive to leave Merge
11. Financial executives to launch Madison chapter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... -- WuXi AppTec, a leading global pharmaceutical, biotechnology ... today announced that it has acquired HD Biosciences ... contract research organization (CRO). After completion of acquisition, ... WuXi, and will continue to focus on growing ... acquisition will further strengthen WuXi,s R&D capability from ...
(Date:1/19/2017)... , Jan. 19, 2017  ArmaGen, Inc., ... Schmidt , Ph.D., as chief executive officer, as ... directors. Dr. Schmidt brings to ArmaGen more than 17 ... research and development of biotherapeutics and pharmaceuticals. ... with the diverse experience and skillset necessary to ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... with services spanning the full spectrum of drug and device development, and ... to pharma/device companies and clinicians, today announced Verified Clinical Trials (VCT) ...
(Date:1/18/2017)... OR (PRWEB) , ... January 18, 2017 , ... ... that provide essential device-to-computer interconnect using USB or PCI Express, announced the ZEM5310 ... Cyclone V E FPGA into a compact business-card sized form factor suitable for ...
Breaking Biology Technology:
(Date:1/6/2017)... 2017  Privately-held CalciMedica, Inc., announced that it ... of a novel calcium release-activated calcium (CRAC) channel ... Acute pancreatitis, sudden painful inflammation of ... can be very serious.  In severe cases it can ... hospital stays, time in the ICU and substantial ...
(Date:1/4/2017)... VEGAS , Jan. 4, 2017  CES ... performance biometric sensor technology, today announced the launch ... sensor systems, the highly-accurate biometric sensor modules ... biometric technology, experience and expertise. The two ... Benchmark designed specifically for hearables, and Benchmark BW2.0, ...
(Date:12/20/2016)... Dec. 20, 2016 The rising popularity ... and leasing is stoking significant interest in keyless ... technology, Bluetooth low energy (BLE), biometrics and near-field ... next wave of wireless technologies in the automotive ... to advanced access systems opens the market to ...
Breaking Biology News(10 mins):